Relying on artificial intelligence, the company has crafted a software tool to assist pathologists in diagnosing cancers and delivering clinical reports.
Its first assay for complete blood counting employs lens-free imaging and a platform that uses a silicon chip to execute operations at the microscale level.
The company will receive an upfront $9.3 million to fund a clinical trial for its NGP phenotyping platform and is eligible for an additional $36 million.
IQuity develops tests that use RNA expression data to predict, detect, and monitor disease, as well as stratify patients by severity of disease.
The grants include funding for five new clinical sites, a new metabolomics core, and increased model organism capabilities.
The goal of the project is to develop a strategy that will increase demand for and access to HIV self-testing among at-risk Nigerian youths.
The researchers will conduct clinical validation in children suspected of having been exposed to high levels of manganese in Chicago.
Of the 1,194 Horizon 2020 proposals received between 2014 and 2017, most were related to the development of IVDs, while a third were focused on personalized medicine.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
Several companies will receive grants to develop hepatitis C molecular point-of-care and core antigen diagnostic assays.